We have decided to focus on triple negative breast cancer (TNBC), as defined by the lack of Estrogen Receptors (ERs) and progesterone receptors (PRs) and by a HER2-negative status, due to its increasingly recognized heterogeneity not only on the molecular level but also on the pathologic and clinical levels [38]. The gene discussed is PGR; the disease is triple-negative breast carcinoma.